How have BPMUF shares performed in 2023?

Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of the year. Since then, BPMUF stock has decreased by 21.2% and is now trading at $41.00. View the best growth stocks for 2023 here .

Are investors shorting Basilea Pharmaceutica?

Basilea Pharmaceutica saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 258,800 shares, a decrease of 9.0% from the October 15th total of 284,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 2,588.0 days. View Basilea Pharmaceutica's Short Interest .

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Basilea Pharmaceutica have any subsidiaries?

The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited. Read More

Basilea Pharmaceutica Stock Price, News & Analysis (OTCMKTS:BPMUF)

$41.00

0.00 (0.00%)

(As of 12/7/2023 ET)

Compare

Today's Range: $41.00
▼
$41.00
50-Day Range: $41.00
▼
$50.00
52-Week Range: $41.00
▼
$41.00

Volume: N/A
Average Volume: N/A
Market Capitalization: $485.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPMUF Stock News Headlines

December 4, 2023 | finance.yahoo.com

Basilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutions

November 20, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

December 8, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 13, 2023 | msn.com

Pfizer unit in pact with Swiss biotech Basilea to sell rights to antifungal

November 13, 2023 | finance.yahoo.com

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

October 31, 2023 | finance.yahoo.com

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

October 19, 2023 | finance.yahoo.com

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

October 17, 2023 | finance.yahoo.com

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

December 8, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

October 2, 2023 | finance.yahoo.com

Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

September 28, 2023 | finance.yahoo.com

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

August 15, 2023 | finance.yahoo.com

Basilea reports strong revenue and profit growth in first half-year 2023

August 4, 2023 | markets.businessinsider.com

Basilea Pharma Submits NDA For Antibiotic Ceftobiprole

August 4, 2023 | finance.yahoo.com

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

June 8, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

April 18, 2023 | finance.yahoo.com

Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole

February 14, 2023 | markets.businessinsider.com

Basilea Pharmaceutica Posts FY Profit

February 14, 2023 | finance.yahoo.com

Basilea reports strong financial results 2022 based on successful implementation of new strategy

February 7, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

January 24, 2023 | markets.businessinsider.com

Basilea Pharma Expects Net Profit In FY22

January 24, 2023 | finance.yahoo.com

Basilea reports preliminary operating profit for 2022, significantly above guidance

January 11, 2023 | finance.yahoo.com

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

January 9, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea

December 28, 2022 | finance.yahoo.com

Basilea announces repayment of 2022 convertible bonds

December 23, 2022 | finance.yahoo.com

Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan

December 19, 2022 | finance.yahoo.com

Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

December 14, 2022 | finance.yahoo.com

Here's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep going

See More Headlines

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BPMUF
CUSIP: N/A
CIK: N/A
Web: www.basilea.com
Phone: (161) 606-1111
Fax: 41-61-606-1112
Employees: 143
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 7.55
Current Ratio: 2.77
Quick Ratio: 2.38

Sales & Book Value

Annual Sales: $154.86 million
Price / Sales: 3.14
Cash Flow: $1.17 per share
Price / Cash Flow: 35.01
Book Value: ($1.83) per share
Price / Book: -22.40

Miscellaneous

Outstanding Shares: 11,851,000
Free Float: N/A
Market Cap: $485.89 million
Optionable: Not Optionable
Beta: 0.82

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David Veitch (Age 58)
Chief Executive Officer
Comp: $1.35M
Mr. Adesh Kaul (Age 49)
Chief Financial Officer
Dr. Gerrit Hauck Ph.D. (Age 59)
Chief Technology Officer
Dr. Laurenz Kellenberger Ph.D. (Age 56)
Chief Scientific Officer
Dr. Marc Engelhardt M.D. (Age 59)
Chief Medical Officer
Dr. Peer Nils Schroder
Head of Corporate Communications & Investor Relations
Mr. Damian Heller (Age 57)
General Counsel & Corporate Secretary
Ms. Ursula Eberhardt (Age 61)
Head of Global Human Resources
Mr. Mark Jones (Age 55)
Head of Project Management & Preclinical Development
Mr. Peter Bielmeier Ph.D. (Age 56)
Head of Global Quality Management

Key Competitors

View All Competitors

BPMUF Stock Analysis - Frequently Asked Questions

How have BPMUF shares performed in 2023?: Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of the year. Since then, BPMUF stock has decreased by 21.2% and is now trading at $41.00.
View the best growth stocks for 2023 here.
Are investors shorting Basilea Pharmaceutica?: Basilea Pharmaceutica saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 258,800 shares, a decrease of 9.0% from the October 15th total of 284,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 2,588.0 days.
View Basilea Pharmaceutica's Short Interest.
How do I buy shares of Basilea Pharmaceutica?: Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Basilea Pharmaceutica have any subsidiaries?: The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More

This page (OTCMKTS:BPMUF) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial